BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, January 31, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2004

View Archived Issues

Farnesoid X receptor agonist protects against liver fibrosis

Read More

JTE-607 induces cardioprotective effects in a rat model of ischemia and reperfusion

Read More

Once-daily mosapride improves constipation in PD patients

Read More

Botulinum toxin A shows promise in the treatment of detrusor overactivity

Read More

Good efficacy and safety profile found for XP-828L in mild to moderate psoriasis

Read More

Novel COX-1 inhibitors prepared and tested at Fujisawa

Read More

Novel PPARdelta agonists identified by Bayer researchers

Read More

Clinical data support the use of gemifloxacin in AECB

Read More

New NO-donating rapamycin derivatives described by NitroMed

Read More

Vertex claims new SHP-2 phosphatase inhibitors and their use

Read More

Novel aggrecanase/MMP-13 inhibitors under study at Japan Tobacco

Read More

Janssen researchers present new PAR-1 antagonists

Read More

New cannabinoid CB1/CB2 ligands and their use claimed by AstraZeneca

Read More

Potential use of a kappa opioid agonist in abdominal pain of IBS

Read More

Neramexane fails to reach statistical significance in phase III Alzheimer's study

Read More

NRP-104 given fast track status for treating cocaine dependence

Read More

Micrologix Biotech completes acquisition of MitoKor

Read More

Chiron acquires Prion Solutions

Read More

Satraplatin plus radiation therapy studies in phase I/II trial for NSCLC

Read More

Exenatide NDA accepted for review

Read More

MGI Pharma to acquire Zycos

Read More

MGI Pharma signs definitive merger agreement to acquire Aesgen

Read More

MGI Pharma and SuperGen sign license agreement for Dacogen

Read More

Positive interim results from phase II trials of TroVax

Read More

NDA submission for Aczone

Read More

Procleix WNV Assay tested on Procleix TIGRIS System under IND

Read More

GlaxoSmithKline acquires Fraxiparine, Fraxodi and Arixtra

Read More

Celsion cleared to conduct phase I study of ThermoDox in liver cancer

Read More

Clarinex syrup approved for use in children with allergies, hives

Read More

Antithrombotic effects of novel coagulation factor Xa inhibitor

Read More

Lethal factor inhibitor effective in anthrax infection

Read More

Dual protease inhibitor effective against inflammatory processes

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing